{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:16:14Z","timestamp":1771046174301,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T00:00:00Z","timestamp":1423180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2014.95","type":"journal-article","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T14:13:29Z","timestamp":1423232009000},"page":"e278-e278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comprehensive genomic profiling identifies a novel TNKS2\u2013PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy"],"prefix":"10.1038","volume":"5","author":[{"given":"Z R","family":"Chalmers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R S","family":"Ohgami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P V","family":"Campregher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G M","family":"Frampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Yelensky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Elvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N A","family":"Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Erlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-A","family":"Vergilio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Chmielecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J S","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P J","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Hermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V A","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C R","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,6]]},"reference":[{"key":"BFbcj201495_CR1","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201\u20131214.","journal-title":"N Engl J Med"},{"key":"BFbcj201495_CR2","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1038\/leu.2012.162","volume":"26","author":"A Pardanani","year":"2012","unstructured":"Pardanani A, D\u2019Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A . Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia 2012; 26: 2439\u20132441.","journal-title":"Leukemia"},{"key":"BFbcj201495_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.leukres.2008.10.004","volume":"33","author":"N Jain","year":"2009","unstructured":"Jain N, Cortes J, Quint\u00e1s-Cardama A, Manshouri T, Luthra R, Garcia-Manero G et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFR\u03b1 mutation status. Leuk Res 2009; 33: 837\u2013839.","journal-title":"Leuk Res"},{"key":"BFbcj201495_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3324\/haematol.12324","volume":"93","author":"A Tefferi","year":"2008","unstructured":"Tefferi A, Verstovsek S, Pardanani A . How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 2008; 93: 6\u20139.","journal-title":"Haematologica"},{"key":"BFbcj201495_CR5","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","volume":"102","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102: 3093\u20133096.","journal-title":"Blood"},{"key":"BFbcj201495_CR6","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","volume":"108","author":"AC Garcia-Montero","year":"2006","unstructured":"Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108: 2366\u20132372.","journal-title":"Blood"},{"key":"BFbcj201495_CR7","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","volume":"99","author":"Y Ma","year":"2002","unstructured":"Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741\u20131744.","journal-title":"Blood"},{"key":"BFbcj201495_CR8","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1158\/1078-0432.CCR-11-2230","volume":"18","author":"C Miranda","year":"2012","unstructured":"Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18: 1769\u20131776.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"BFbcj201495_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023\u20131031.","journal-title":"Nat Biotechnol"},{"key":"BFbcj201495_CR10","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754\u20131760.","journal-title":"Bioinformatics"},{"key":"BFbcj201495_CR11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1038\/leu.2008.287","volume":"22","author":"J Gotlib","year":"2008","unstructured":"Gotlib J, Cools J . Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008; 22: 1999\u20132010.","journal-title":"Leukemia"},{"key":"BFbcj201495_CR12","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1073\/pnas.0601192103","volume":"103","author":"EH Stover","year":"2006","unstructured":"Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P et al. Activation of FIP1L1\u2013PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA 2006; 103: 8078\u20138083.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201495_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1159\/000365326","volume":"7","author":"NA Palma","year":"2014","unstructured":"Palma NA, Ali SM, O\u2019Connor J, Dutta D, Wang K, Soman S et al. Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary. Case Rep Oncol 2014; 7: 503\u2013508.","journal-title":"Case Rep Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201495","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201495.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:56:59Z","timestamp":1672912619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,6]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2]]}},"alternative-id":["BFbcj201495"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2014.95","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,6]]},"assertion":[{"value":"6 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ZRC, SMA, GMF, JSR, RY, NAP, JAE, JC, PJS, VAM, RE and PVC are employed by and have equity interest in Foundation Medicine, Inc. The remaining authors declared no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}